<DOC>
	<DOCNO>NCT00306202</DOCNO>
	<brief_summary>The purpose clinical research study establish recommend phase 2 daily ( QD ) dose dasatinib ass efficacy investigational drug relapse refractory ( resistant previous treatment ) leukemia child adolescent . The side effect oral investigational drug may child , level drug blood , study different dos .</brief_summary>
	<brief_title>Study Dasatinib Children Adolescents With Relapsed Refractory Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Phpositive ( Ph+ ) Chronic Myelogenous Leukemia chronic , accelerate blast phase Ph+ acute lymphoblastic leukemia ( ALL ) imatinibresistant disease intolerance imatinib . Phnegative acute leukemia second subsequent relapse Age &gt; 1 &lt; 21 year Lansky Karnofsky scale &gt; 60 Life expectancy &gt; 3 week Adequate hepatic renal function Written inform consent Subjects potentiallycurative therapy available , include elect immediate [ ie , plan &lt; 45 day ] stemcell transplantation . Subjects Stratum 1 ongoing identical HLA donor search , may discontinue study donor become available . ) Subjects symptomatic central nervous system ( CNS ) disease ( eg , convulsion due CNS disease ) . Subjects recover acute toxicity previous therapy . Clinicallysignificant disorder platelet function ( eg , von Willebrand 's disease ) ongoing gastrointestinal bleeding . Serious uncontrolled medical disorder active infection Uncontrolled significant cardiovascular disease Use investigational agent anticancer agent within 14 day prior treatment start . Prior therapy dasatinib Subjects take medication irreversibly inhibit platelet function anticoagulant . Subjects take certain medication accept risk cause QTc prolongation . Women Child Bearing Potential positive pregnancy test prior study drug administration . Expected noncompliance , unable regular followup due psychologic , social , familial , geographic reason . Subjects compulsorily detain legal reason treatment either psychiatric physical ( eg , infectious disease ) illness must enrol study .</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Relapsed Refractory Leukemia</keyword>
</DOC>